By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- New research on Biotechnology is the subject of a report. According to news reporting from Shenyang, People's Republic of China, by NewsRx journalists, research stated, "Both BRCA1 and epidermal growth factor receptor (EGFR) play a critical role in ovarian cancer progression. However, the crosstalk between BRCA1 and EGFR signaling pathways in ovarian cancer remains largely unknown."
The news correspondents obtained a quote from the research from China Medical University and Hospital, "The effect of BRCA1 on EGFR was assessed in 146 serous ovarian cancer patients (28 pairs of BRCA1-mutated or not, 23 pairs of BRCA2-mutated or not, and 22 pairs with hypermethylated BRCA1 promoter or not). BRCA1 promoter methylation was analyzed by bisulfite sequencing using primers flanking the core promoter region. Expression levels of BRCA1 and EGFR were assessed by immunohistochemistry and real-time PCR. The knockdown and overexpression of BRCA1 were achieved using a lentiviral vector in 293 T cells, SKOV3 ovarian cancer cells, and primary non-mutated and BRCA1-mutated ovarian cancer cells. EGFR expression was increased in all cancer tissues compared to normal tissues. Additionally, EGFR expression was higher in normal tissues of BRCA1-mutated patients, and was further increased in cancer tissues; EGFR levels were also significantly elevated in ovarian cancer with promoter hypermethylation-mediated inactivation of BRCA1. BRCA1 knockdown was an effective way to activate EGFR expression in ovarian cancer cells."
According to the news reporters, the research concluded: "These results indicate that BRCA1 may be a potential trigger in transcriptional regulation of EGFR in the development of ovarian cancer."
For more information on this research see: Effect of BRCA1 on epidermal growth factor receptor in ovarian cancer. Journal of Experimental & Clinical Cancer Research, 2013;32(1):102. (BioMed Central - www.biomedcentral.com/; Journal of Experimental & Clinical Cancer Research - www.jeccr.com)
Our news journalists report that additional information may be obtained by contacting D. Li, Dept. of Obstetrics and Gynecology, Shengjing Hospital, China Medical University, No, 36, Sanhao Street, Heping District, Shenyang 110004, People's Taiwan. Additional authors for this research include F.F. Bi, J.M. Cao, C. Cao, C.Y. Li and Q. Yang (see also Biotechnology).
Keywords for this news article include: Asia, Biotechnology, BRCA1, Shenyang, Genetics, Oncology, Gynecology, Ovarian Cancer, Women's Health, Membrane Proteins, Peptide Receptors, Cancer Gene Therapy, Growth Factor Receptors, People's Republic of China.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC